Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.

Xavière Panhard, Adeline Samson
Author Information
  1. Xavière Panhard: INSERM U738 and UFR de Médecine, University Paris 7, 16 rue Huchard, 75018 Paris, France. xaviere.panhard@bichat.inserm.fr

Abstract

This article focuses on parameter estimation of multilevel nonlinear mixed-effects models (MNLMEMs). These models are used to analyze data presenting multiple hierarchical levels of grouping (cluster data, clinical trials with several observation periods, ...). The variability of the individual parameters of the regression function is thus decomposed as a between-subject variability and higher levels of variability (e.g. within-subject variability). We propose maximum likelihood estimates of parameters of those MNLMEMs with 2 levels of random effects, using an extension of the stochastic approximation version of expectation-maximization (SAEM)-Monte Carlo Markov chain algorithm. The extended SAEM algorithm is split into an explicit direct expectation-maximization (EM) algorithm and a stochastic EM part. Compared to the original algorithm, additional sufficient statistics have to be approximated by relying on the conditional distribution of the second level of random effects. This estimation method is evaluated on pharmacokinetic crossover simulated trials, mimicking theophylline concentration data. Results obtained on those data sets with either the SAEM algorithm or the first-order conditional estimates (FOCE) algorithm (implemented in the nlme function of R software) are compared: biases and root mean square errors of almost all the SAEM estimates are smaller than the FOCE ones. Finally, we apply the extended SAEM algorithm to analyze the pharmacokinetic interaction of tenofovir on atazanavir, a novel protease inhibitor, from the Agence Nationale de Recherche sur le Sida 107-Puzzle 2 study. A significant decrease of the area under the curve of atazanavir is found in patients receiving both treatments.

References

  1. Stat Med. 2007 Mar 15;26(6):1268-84 [PMID: 16810714]
  2. Genet Sel Evol. 2006 Nov-Dec;38(6):583-600 [PMID: 17129561]
  3. Biometrics. 2004 Mar;60(1):16-24 [PMID: 15032769]
  4. Crit Rev Biomed Eng. 1982;8(3):195-222 [PMID: 6754254]
  5. Biometrics. 1990 Sep;46(3):673-87 [PMID: 2242409]
  6. Stat Med. 2007 Nov 30;26(27):4860-75 [PMID: 17562540]
  7. J Pharmacokinet Biopharm. 1993 Dec;21(6):735-50 [PMID: 8138894]
  8. Stat Med. 2005 May 30;24(10):1509-24 [PMID: 15761916]

MeSH Term

Algorithms
Anti-HIV Agents
Area Under Curve
Atazanavir Sulfate
Bias
Biometry
Cluster Analysis
Cross-Over Studies
Drug Interactions
Humans
Likelihood Functions
Markov Chains
Monte Carlo Method
Nonlinear Dynamics
Oligopeptides
Pyridines
Regression Analysis
Theophylline
Therapeutic Equivalency
Time Factors

Chemicals

Anti-HIV Agents
Oligopeptides
Pyridines
Atazanavir Sulfate
Theophylline

Word Cloud

Created with Highcharts 10.0.0algorithmSAEMdatalevelsvariabilitymodelsestimates2randomeffectsestimationnonlinearMNLMEMsanalyzetrialsparametersfunctionstochasticexpectation-maximizationextendedEMconditionalpharmacokineticFOCEatazanavirarticlefocusesparametermultilevelmixed-effectsusedpresentingmultiplehierarchicalgroupingclusterclinicalseveralobservationperiodsindividualregressionthusdecomposedbetween-subjecthigheregwithin-subjectproposemaximumlikelihoodusingextensionapproximationversion-MonteCarloMarkovchainsplitexplicitdirectpartComparedoriginaladditionalsufficientstatisticsapproximatedrelyingdistributionsecondlevelmethodevaluatedcrossoversimulatedmimickingtheophyllineconcentrationResultsobtainedsetseitherfirst-orderimplementednlmeRsoftwarecompared:biasesrootmeansquareerrorsalmostsmalleronesFinallyapplyinteractiontenofovirnovelproteaseinhibitorAgenceNationaledeRecherchesurleSida107-PuzzlestudysignificantdecreaseareacurvefoundpatientsreceivingtreatmentsExtensionmixed

Similar Articles

Cited By